Motoo Araki

Prof. Motoo Araki

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
WLWenfeng Lin
Wenfeng Lin
CLChaoming Li
Chaoming Li
NXNaijin Xu
Naijin Xu
MWMasami Watanabe
Masami Watanabe
RXRuizhi Xue
Ruizhi Xue
PHPeng HUANG
Peng HUANG
Purpose: With the advance of screening techniques, there is a growing number of low-risk or intermediate-risk prostate cancer (PCa) cases, remaining a serious threat to men’s health. To obtain better efficacy, a growing interest has been attracted to develop such emerging treatments as immunotherapy and focal therapy. However, few studies offer guidance on whether and how to combine these modalities against PCa. This study was designed to develop dual-functional nanoparticles (NPs) which combined photothermal therapy (PTT) with immunotherapy and determine the anti-tumor efficacy for PCa treatment. Methods: By a double emulsion technique, the drug nanocarrier, poly(lactic-co-glycolic acid) or PLGA, was applied for co-loading of a fluorescent dye, indocyanine green (ICG) and a toll-like receptor 7/8 (TLR7/8) agonist resiquimod (R848) to synthesize PLGA-ICG-R848 NPs. Next, we determined their characteristic features and evaluated whether they inhibited the cell viability in multiple PCa cell lines. After treatment with PLGA-ICG-R848, the maturation markers of bone marrow-derived dendritic cells (BMDCs) were detected by flow cytometry. By establishing a subcutaneous xenograft model of mouse PCa, we explored both the anti-tumor effect and immune response following the NPs-based laser ablation. Results: With a mean diameter of 157.7 nm, PLGA-ICG-R848 exhibited no cytotoxic effect in PCa cells, but they significantly decreased RM9 cell viability to (3.9± 1.0)% after laser irradiation. Moreover, PLGA-ICG-R848 promoted BMDCs maturation with the significantly elevated proportions of CD11c+CD86+ and CD11c+CD80+ cells. Following PLGA-ICG-R848-based laser ablation in vivo, the decreased bioluminescent signals indicated a significant inhibition of PCa growth, while the ratio of splenic natural killer (NK) cells in PLGA-ICG-R848 was (3.96± 1.88)% compared with (0.99± 0.10)% in PBS group, revealing the enhanced immune response against PCa. Conclusion: The dual-functional PLGA-ICG-R848 NPs under laser irradiation exhibit the anti-tumor efficacy for PCa treatment by combining PTT with immunotherapy.

31 January 2012 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MAMotoo Araki
Motoo Araki
TSTakashi Saika
Takashi Saika
DADaiji Araki
Daiji Araki
YKYasuyuki Kobayashi
Yasuyuki Kobayashi
SUShinya Uehara
Shinya Uehara
HKHiromi Kumon
Hiromi Kumon

1 January 2002 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MAMotoo Araki
Motoo Araki
RKReiko Kariyama
Reiko Kariyama
KMKoichi Monden
Koichi Monden
MTMasaya Tsugawa
Masaya Tsugawa
HKHiromi Kumon
Hiromi Kumon

22 April 2021 in Transplant International
Verified
Journal Article
Closed access
PDF file
YOYoshitsugu Obi
Yoshitsugu Obi
NINaotsugu Ichimaru
Naotsugu Ichimaru
YSYusuke Sakaguchi
Yusuke Sakaguchi
KIKazuhiro Iwadoh
Kazuhiro Iwadoh
DIDaisuke Ishii
Daisuke Ishii
TIthe CANDLE‐KIT Trial Investigators
the CANDLE‐KIT Trial Investigators
Anemia and vitamin D deficiency are associated with allograft failure, and hence, are potential therapeutic targets among kidney transplant recipients (KTRs). We conducted a multicenter, two‐by‐two factorial, open‐label, randomized clinical trial to examine the effects of anemia correction and vitamin D supplementation on 2‐year change in eGFR among KTRs (CANDLE‐KIT). We enrolled 153 patients with anemia and >1‐year history of transplantation across 23 facilities in Japan, and randomly assigned them to either a high or low hemoglobin target (>12.5 vs. <10.5 g/dL) and to either cholecalciferol 1000 IU/day or control. This trial was terminated early based on the planned interim intention‐to‐treat analyses (α=0.034). Among 125 patients who completed the study, 2‐year decline in eGFR was smaller in the high vs. low hemoglobin group (i.e., ‐1.6±4.5 vs. ‐4.0±6.9 mL/min/1.73 m2; P=0.021), but did not differ between the cholecalciferol and control groups. These findings were supported by the fully‐adjusted mixed effects model evaluating the rate of eGFR decline among all 153 participants. There were no significant between‐group differences in all‐cause death or the renal composite outcome in either arm. In conclusion, aggressive anemia correction showed a potential to preserve allograft kidney function.

22 February 2020 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
TYTakashi Yoshioka
Takashi Yoshioka
TITatsuyoshi Ikenoue
Tatsuyoshi Ikenoue
HHHideaki Hashimoto
Hideaki Hashimoto
HOHideo Otsuki
Hideo Otsuki
TOTadashi Oeda
Tadashi Oeda
YYYosuke Yamamoto
Yosuke Yamamoto
Purpose: To develop and validate a new clinical prediction model that accurately predicts the failure of shockwave lithotripsy (SWL) using information obtained from non-contrast-enhanced computed tomography (NCCT). Methods: This multicentre retrospective cohort study consecutively enrolled patients diagnosed with upper urinary tract calculi by NCCT at five hospitals in Japan from January 1, 2006 to December 31, 2016. Among the candidate predictors, we selected the six most significant predictors a priori. The main outcome was SWL failure after three sessions. Model calibration was evaluated by the calibration slope and the Hosmer–Lemeshow test. Discrimination was evaluated by the receiver-operating characteristic curves and the area under the curve (AUC). A multivariable logistic regression analysis was performed; based on the estimated β coefficients, predictive scores were generated. Results: Of 2695 patients, 2271 were included. Patients were divided into the development cohort (1666 patients) and validation cohort (605 patients) according to geographical factors. We developed a clinical prediction model with scores ranging from 0 to 49 points. We named the prediction model the S3HoCKwave score based on the initials of the predictors (sex, skin-to-stone distance, size, Hounsfield units, colic, and kidney or ureter). As a result of internal validation, the optimism-corrected AUC was 0.72. In the validation cohort, the Hosmer–Lemeshow test did not show statistical significance (P = 0.33), and the AUC was 0.71 (95% confidence interval 0.65–0.76). Conclusions: The S3HoCKwave score is easy to understand, has a relatively high predictive value, and allows clinicians to make appropriate treatment selections.

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
NXNaijin Xu
Naijin Xu
WLWenfeng Lin
Wenfeng Lin
JSJingkai Sun
Jingkai Sun
TSTakuya Sadahira
Takuya Sadahira
AXAbai Xu
Abai Xu
PHPeng HUANG
Peng HUANG
Nitroxoline is considered to be an effective treatment for the urinary tract infections. Recently, it has been found to be effective against several cancers. However, few studies have examined the anti-tumor activity of nitroxoline in bladder cancer. The purpose of the study was to reveal the possible mechanisms how nitroxoline inhibited bladder cancer progression. In vitro assay, we demonstrated that nitroxoline inhibited bladder cancer cell growth and migration in a concentration-related manner. Western blot analysis demonstrated that nitroxoline downregulated the expressions of epithelial mesenchymal transition (EMT)-related proteins. Furthermore, treatment with nitroxoline in the C3H/He mice bladder cancer subcutaneous model resulted in significant inhibition of tumor growth. Moreover, the percentage of myeloid‐derived suppressor cells (MDSC) in peripheral blood cells significantly decreased after treatment of nitroxoline. Taken together, our results suggested that nitroxoline may be used as a potential drug for bladder cancer.